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Magnitude of and Prognostic Factors Associated With 1-Year
Mortality After Hospital Discharge for Acute Decompensated Heart
Failure Based on Ejection Fraction Findings
Andrew H. Coles, PhD; Mayra Tisminetzky, MD, PhD; Jorge Yarzebski, MD, MPH; Darleen Lessard, MS; Joel M. Gore, MD;
Chad E. Darling, MD; Robert J. Goldberg, PhD
Background-—Limited data exist about the magnitude of and the factors associated with prognosis within 1 year for patients
discharged from the hospital after acute decompensated heart failure. Data are particularly limited from the more generalizable
perspective of a population-based investigation and should be further stratiﬁed according to currently recommended ejection
fraction (EF) ﬁndings.
Methods and Results-—The hospital medical records of residents of the Worcester, Massachusetts, metropolitan area who were
discharged after acute decompensated heart failure from all 11 medical centers in central Massachusetts during 1995, 2000,
2002, 2004, and 2006 were reviewed. The average age of the 4025 study patients was 75 years, 93% were white, and 44% were
men. Of these, 35% (n=1414) had reduced EF (≤40%), 13% (n=521) had borderline preserved EF (41–49%), and 52% (n=2090) had
preserved EF (≥50%); at 1 year after discharge, death rates were 34%, 30%, and 29%, respectively (P=0.03). Older age, a history of
chronic obstructive pulmonary disease, systolic blood pressure ﬁndings <150 mm Hg on admission, and hyponatremia were
important predictors of 1-year mortality for all study patients, whereas several comorbidities and physiological factors were
differentially associated with 1-year death rates in patients with reduced, borderline preserved, and preserved EF.
Conclusions-—This population-based study highlights the need for further contemporary research into the characteristics,
treatment practices, natural history, and long-term outcomes of patients with acute decompensated heart failure and varying EF
ﬁndings and reinforces ongoing discussions about whether different treatment guidelines may be needed for these patients to
design more personalized treatment plans. ( J Am Heart Assoc. 2015;4:e002303 doi: 10.1161/JAHA.115.002303)
Key Words: acute heart failure • ejection fraction ﬁndings • population-based study
A cute decompensated heart failure (ADHF) is a worldwideepidemic that affects nearly 1 million US adults and
results in considerable morbidity, functional disability, and
mortality.1 To better understand and characterize the epi-
demiology of this increasingly prevalent clinical syndrome, a
classiﬁcation schema for heart failure (HF) has been recently
created based on ejection fraction (EF) ﬁndings.2 The 2013
American Heart Association/American College of Cardiology
(AHA/ACC) guidelines characterized 3 EF strata as preserved
EF (pEF; ≥50%), reduced EF (rEF; ≤40%), and borderline
preserved EF (BpEF; 41–49%).2 This new classiﬁcation schema
was recommended because several research groups had used
different EF cutoffs for differentiating patients with pEF from
those with rEF ﬁndings, producing varying study results and
difﬁculties in interpretation and extrapolation.
Prior epidemiological studies have identiﬁed a number of
important prognostic factors associated with poor long-term
outcomes for patients with ADHF including advanced age,
male sex, hyponatremia, lower systolic blood pressure, poorer
kidney function, and several comorbid conditions.3–12 Many of
these earlier studies examined the role of various prognostic
factors in patients with HF that had not further been stratiﬁed
according to EF ﬁndings, and among those that did,11,13–17
none used the 2013 AHA/ACC guidelines recommending
speciﬁc EF cut points.2 Furthermore, few data exist on the
prognosis or the factors associated with poor long-term
prognosis for patients with BpEF values, especially from the
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more generalizable perspective of a population-based
investigation.
The main objectives of the present communitywide study
were to describe the factors that inﬂuence all-cause mortality
during the ﬁrst year after hospital discharge among patients
with ADHF who were further categorized by currently
recommended EF strata and cut points and by age. A
secondary study objective was to describe differences in the
medications prescribed and the procedures received at the
time of hospital discharge for patients who survived the ﬁrst
year after hospital discharge in comparison with those who
died. Data from the population-based Worcester Heart Failure
Study were used for this investigation.18–21
Methods
Study Population
The study population consisted of adult residents of the
Worcester, Massachusetts, metropolitan area (2010 census
estimate of 518 000) who survived hospitalization for ADHF
at all 11 central Massachusetts medical centers during the 5
study years of 1995, 2000, 2002, 2004, and 2006 and who
had undergone an echocardiogram during the acute index
hospitalization (n=4025). These study years were chosen
based on grant funding availability.
Details of the Worcester Heart Failure Study have been
described previously.18–21 In brief, trained nurses and physi-
cians reviewed the medical records of patients with primary
and/or secondary International Classiﬁcation of Diseases, 9th
Revision (ICD-9), discharge diagnoses consistent with the
possible presence of HF (ICD-9 code 428). In addition, the
hospital medical records of patients with discharge diagnoses
of hypertensive heart and renal disease, acute cor pulmonale,
cardiomyopathy, pulmonary congestion, acute lung edema,
and respiratory abnormalities were reviewed to identify
hospitalized residents of central Massachusetts who may
have had new-onset ADHF. The Framingham criteria (pres-
ence of 2 major criteria or the presence of 1 major and 2
minor criteria) were used to conﬁrm the diagnosis of HF.22
All doubtful or questionable cases of ADHF were initially
reviewed by the principal investigator in conjunction with the
project coordinator and then by the senior cardiologist and
internist panel. Doubtful or questionable cases of ADHF were
deﬁned as those in which there was uncertainty as to whether
HF had occurred during the admission of interest, and only
deﬁnite cases of ADHF were included in this investigation.
Excluded from the study were patients with a principal
diagnosis of acute myocardial infarction (ICD-9 codes 410.0
to 410.99), cases of HF secondary to a surgical procedure (eg,
coronary artery bypass grafting) or to ﬂuid overload (eg,
during hemodialysis), and all medical records with a principal
diagnosis of chest pain (eg, ICD-9 code 786.5). This study was
approved by the institutional review board at the University of
Massachusetts Medical School. Informed consent was
waived.
Data Collection
Patient demographic characteristics (eg, age, sex), medical
history (eg, diabetes, hypertension, stroke), clinical charac-
teristics, and laboratory test results (eg, serum sodium, blood
urea nitrogen [BUN]) were collected from the review of
inpatient medical records. Although we collected information
about kidney function through the measurement of the
estimated serum glomerular ﬁltration rate and BUN ﬁndings,
these measures are highly correlated, and BUN ﬁndings have
been shown to be more predictive of adverse events in
patients with ADHF than estimated glomerular ﬁltration rate
ﬁndings.23 Consequently, we presented data only on serum
BUN ﬁndings.
All EF measurements were ascertained by results from a
transthoracic echocardiogram during each patient’s index
hospitalization for ADHF. The rEF was deﬁned as a patient
with ADHF who had an EF value ≤40%, pEF was deﬁned as an
EF value ≥50%, and BpEF was classiﬁed as being present in
patients with an EF value between 41% and 49%. These 3 cut
points were chosen based on currently recommended 2013
AHA/ACC guidelines.2
Physicians’ progress notes and daily medication logs were
reviewed for prescription of selected medications and med-
ication classes at the time of hospital discharge, including
angiotensin-converting enzyme inhibitors (ACEIs) and angio-
tensin receptor blockers (ARBs), aldosterone inhibitors,
aspirin, beta blockers, calcium channel blockers, digoxin,
diuretics, lipid-lowering agents, and nitrates. Postdischarge
survival status for all conﬁrmed cases of ADHF was obtained
by the review of medical records at all participating medical
centers for further hospitalizations or medical care contacts
and review of Social Security Death Index and statewide death
certiﬁcates. Follow-up of all patient cohorts was through
calendar year 2011.
Data Analysis
We examined differences in the characteristics of patients in
the 3 mutually exclusive EF strata using ANOVA and v2 tests
for continuous and discrete variables, respectively. A life table
analysis was performed to estimate postdischarge death rates
including patients with varying duration of follow-up. Cox
proportional hazards regression models were used to examine
the association between various prognostic factors and
1-year postdischarge mortality, further stratiﬁed according
to EF ﬁndings. This time point was chosen for analysis
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because of the particularly high death rates experienced by
patients with ADHF after discharge from the hospital. The
factors chosen for inclusion in the regression models were
based on established predictors of mortality in the published
literature and differences between the EF groups at baseline,
deﬁned as P<0.05. We did not control for the receipt of
cardiac medications during the index hospitalization because
of the potential for confounding by treatment indication,
difﬁculties in interpretation, and lack of more detailed
information about the timing of therapy administration relative
to the onset of ADHF. The Committee for the Protection of
Human Subjects in Research at the University of Mas-
sachusetts Medical School approved this study.
Results
Study Population Characteristics
During the 5 years under study, a total of 4025 residents of
central Massachusetts were discharged from all 11 Worcester
metropolitan medical centers after ADHF and had echocar-
diography results available during their index hospitalization.
The average age of this population was approximately
75 years, the majority of patients were white, and 56% were
women. In this population, 35% (n=1414) of patients were
considered to have rEF (EF ≤40%), 13% (n=521) had BpEF (EF
41–49%), and 52% (n=2090) were classiﬁed as having pEF (EF
≥50%).
Postdischarge Survival
Overall, 34% (n=474) of the patients with rEF, 30% (n=157) of
the patients with BpEF, and 29% (n=614) of the patients with
pEF died during the ﬁrst year after hospital discharge for
ADHF (P=0.03). The median survival times were 2.4, 2.3, and
2.7 years after hospital discharge for patients with rEF, BpEF,
and pEF, respectively. There was an important decline in the
proportion of patients who died during the ﬁrst year under
study (1995) compared with the most recent year under
investigation (2006) among those with rEF (41% in 1995
versus 24% in 2006) and pEF (35% versus 26%) but not among
those with BpEF (28% versus 30%) (Figure).
Characteristics of Deceased Patients
We examined the differences in the characteristics of patients
who died compared with those who survived the ﬁrst year
after hospital discharge in the 3 EF strata. Patients who died
were signiﬁcantly older (79 versus 74 years), were more likely
to be white (96% versus 92%), had a longer stay in the hospital
(7.9 versus 6.0 days), and were more likely to have been
diagnosed previously with chronic obstructive pulmonary
disease (COPD; 37.1% versus 29.5%), atrial ﬁbrillation
(43.1% versus 32.3%), and HF (68.0% versus 57.2%). In
addition, patients who died within the ﬁrst year after hospital
discharge had signiﬁcantly lower average blood pressures
(diastolic 71.9 versus 78.4 mm Hg; systolic 138.3 versus
148.8 mm Hg) but signiﬁcantly higher BUN levels (37.9 ver-
sus 28.4 mg/dL).
In terms of the speciﬁc EF strata, patients with rEF who
died within 1 year after hospital discharge were more likely to
have been previously diagnosed with chronic kidney disease,
peripheral vascular disease, and coronary heart disease
(Table 1). In addition, these patients had lower serum sodium
and hematocrit ﬁndings at the time of hospital admission but
higher BUN values. Patients with BpEF who died were more
likely to have been previously diagnosed with atrial ﬁbrillation
and HF than those who survived this period and had higher
BUN ﬁndings. Patients with pEF that died during this high-risk
period were more likely to have a history of either chronic
kidney disease or peripheral vascular disease, were less likely
to have a history of hypertension, and had lower serum
hematocrit ﬁndings but higher BUN levels at the time of
hospital admission than those who survived the ﬁrst year after
hospital discharge for ADHF. The vast majority of patients
with ADHF were admitted to the 3 major teaching and
community hospitals in central Massachusetts.
Hospital Medication Use by EF Strata
Prescribing patterns of selected discharge medications for
patients with ADHF further stratiﬁed according to EF ﬁndings
were evaluated, with several between-group differences
noted. Patients with pEF were less likely to have been
prescribed ACEIs and ARBs (72% for patients with rEF, 56% for
patients with BpEF, and 44% for patients with pEF) and digoxin
(56%, 36%, and 22%, respectively) at the time of hospital
discharge for ADHF (P<0.01). Patients with pEF, however,
were signiﬁcantly more likely to have been prescribed calcium
channel blockers at the time of hospital discharge than either
Figure. Trends in 1-year postdischarge mortality according to
ejection fraction ﬁndings.
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of the other EF comparison groups (13% for rEF, 28% for BpEF,
and 33% for pEF; P<0.01).
We examined possible differences in the medications
prescribed at hospital discharge for patients who survived the
ﬁrst year after discharge in comparison to those who died,
further stratiﬁed according to EF ﬁndings (Table 2). Patients
with rEF who died during this period were signiﬁcantly less
likely to have been prescribed ACEIs or ARBs, aldosterone
inhibitors, aspirin, beta blockers, and lipid-lowering agents
than those who survived but were more likely to have been
prescribed nitrate therapy (Table 2). Patients with BpEF who
died were signiﬁcantly less likely to have been prescribed
aspirin, beta blockers, lipid-lowering agents, and nitrates but
were more likely to have been prescribed digoxin than those
who survived the ﬁrst year after hospital discharge. Patients
with pEF who died were signiﬁcantly less likely to have been
prescribed ACEIs or ARBs, aspirin, beta blockers, and
lipid-lowering agents but were more likely to have been
Table 1. Characteristics of Patients With Acute Decompensated Heart Failure After Hospital Discharge According to Ejection
Fraction Findings and 1-Year Survival Status
Demographics
rEF (EF ≤40%) BpEF (EF=41–49%) pEF (EF ≥50%)
Alive (n=940) Dead (n=474) Alive (n=364) Dead (n=157) Alive (n=1476) Dead (n=614)
Age (mean, y) 71.4 77.1** 74.4 80.0** 75.7 79.6**
<65, n (%) 245 (26.1) 64 (13.5) 66 (18.1) 7 (4.5) 260 (17.6) 55 (9.0)*
65 to 74 247 (26.3) 85 (17.9) 87 (23.9) 30 (19.1) 288 (19.5) 98 (16.0)*
75 to 84 317 (33.7) 200 (42.2) 144 (39.6) 69 (44.0)* 561 (38.0) 232 (37.9)*
≥85 131 (13.9) 125 (26.4) 67 (18.4) 51 (32.5)* 367 (24.9)* 228 (37.2)*
Male, n (%) 564 (60.0) 274 (57.8) 164 (45.1) 74 (47.1) 490 (33.2) 203 (33.1)
White, n (%) 845 (89.9) 451 (95.2)** 334 (91.8) 151 (96.2) 1362 (92.3) 590 (96.1)*
Length of stay (mean, days) 6.2 7.4** 5.9 7.6* 5.9 8.9**
Teaching hospital 835 (88.8) 443 (93.5)** 327 (89.8) 137 (87.3) 1323 (89.6) 544 (88.6)
Comorbidities, n (%)
Atrial fibrillation 312 (33.2) 187 (39.5)* 111 (30.5) 69 (44.0)* 492 (33.3) 282 (45.9)**
Cancer 146 (15.5) 112 (23.6)* 88 (24.2) 43 (27.4) 275 (18.6) 164 (26.7)*
Chronic kidney disease 217 (23.1) 186 (39.2)** 87 (23.9) 49 (31.2) 306 (20.7) 182 (29.6)**
COPD 242 (25.7) 148 (31.2)* 107 (29.4) 66 (42.0)* 492 (33.3) 234 (38.1)*
Coronary heart disease 497 (52.9) 308 (65.0)** 191 (52.5) 95 (60.5) 658 (44.6) 279 (45.4)
Diabetes 353 (37.6) 191 (40.3) 144 (39.6) 71 (45.2) 529 (35.8) 205 (33.4)
Heart failure 578 (61.5) 356 (75.1)** 199 (54.7) 105 (66.9)* 816 (55.3) 380 (61.9)*
Hypertension 632 (67.2) 324 (68.4) 274 (75.3) 109 (69.4) 1110 (75.2) 425 (69.2)*
Liver disease/failure 31 (3.3) 15 (3.2) 10 (2.8) 6 (3.8) 38 (2.6) 19 (3.1)
Peripheral vascular disease 154 (16.4) 132 (27.9)** 90 (24.7) 33 (21.0) 278 (18.8) 135 (22.0)**
Stroke 108 (11.5) 68 (14.4) 50 (13.7) 30 (19.1) 175 (11.9) 80 (13.0)
Laboratory and physiologic variables, meanSD
Blood urea nitrogen, mg/dL 27.718.2 42.324.6** 30.019.6 36.021.7* 27.517.4 35.422.6**
Diastolic blood pressure, mm Hg 81.419.4 72.218.1** 78.618.7 72.717.1* 75.119.2 70.819.7**
Glucose, mg/dL 158.568.7 153.264.9 161.975.5 158.870.1 153.965.6 149.962.7
Hematocrit (%) 38.16.5 36.46.4** 36.16.3 35.36.4 36.413.1 34.76.2*
Sodium, mEq/L 137.95.4 136.95.0* 137.94.2 137.74.9 137.85.0 137.37.2
Systolic blood pressure, mm Hg 144.230.0 130.1 28.4** 151.932.9 142.329.3* 150.431.8 142.432.1**
Total cholesterol, mg/dL 158.142.9 148.639.2 157.638.8 145.244.3 158.542.6 152.546.2
ACEIs indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BpEF, borderline preserved ejection fraction; COPD, chronic obstructive pulmonary disease;
EF, ejection fraction; pEF, preserved ejection fraction; rEF, reduced ejection fraction.
*P<0.05.
**P<0.001.
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prescribed digoxin than patients who survived this period
(Table 2).
Patients who died during this 1-year period were also more
likely not to have been prescribed any cardiac medication
(ACEIs or ARBs, beta blockers, and aldosterone antagonists),
regardless of EF strata (Table 2). Patients from all 3 EF strata
who were prescribed >2 cardiac medications at the time of
hospital discharge for ADHF were more likely to have survived
the ﬁrst year after hospital discharge than patients who had
been prescribed fewer cardiac medications, and these trends
were most evident for those with BpEF (Table 2). Few patients
in each study group underwent dialysis or received implanted
cardiac-support devices.
Factors Associated With 1-Year Mortality for
Patients With ADHF by EF Strata
After adjusting for a number of important clinical and
demographic variables, the 4 statistically signiﬁcant factors
that were associated with a greater risk for dying during the
ﬁrst year after hospital discharge across all 3 EF strata were
advanced age, a history of previously diagnosed COPD,
systolic blood pressure <150 mm Hg at the time of hospital
admission, and serum sodium ﬁndings <135 mg/dL.
Among patients with rEF after multivariable adjustment, a
history of peripheral vascular disease and elevated BUN levels
were signiﬁcantly associated with an increased risk of dying
(Table 3). Among patients with BpEF, no additional factors
were signiﬁcantly associated with an increased risk of dying at
1 year. Among patients with pEF, a history of atrial ﬁbrillation,
absence of a history of hypertension, low hematocrit ﬁndings,
and elevated BUN values at the time of hospital admission were
associated with higher 1-year death rates after hospital
discharge (Table 3). We also carried out an additional regres-
sion analysis in which we controlled for potential heterogeneity
among participating medical centers and found no differences
in the factors associated with 1-year death rates in the models
with and without this variable (data not shown).
Table 2. Hospital Discharge Medications and Procedures According to Ejection Fraction Findings and 1-Year Survival Status
Medication, n (%)
rEF (EF ≤40%) BpEF (EF=41–49%) pEF (EF ≥50%)
Alive (n=940) Dead (n=474) Alive (n=364) Dead (n=157) Alive (n=1476) Dead (n=614)
ACEIs/ARBs 724 (77.0) 292 (61.6)* 212 (58.2) 82 (52.2) 692 (46.9) 226 (36.8)*
Aldosterone inhibitors 110 (11.7) 39 (8.2)* 19 (5.2) 4 (2.6) 63 (4.3) 20 (3.3)
Aspirin 555 (59.0) 236 (49.8)* 191 (52.5) 71 (45.2)** 749 (50.8) 240 (39.1)*
Beta blockers 597 (63.5) 230 (48.5)* 231 (63.5) 77 (49.0)* 855 (57.9) 300 (48.9)*
Calcium channel blockers 128 (13.6) 55 (11.6) 104 (28.6) 42 (26.8) 474 (32.1) 214 (34.9)
Digoxin 523 (55.6) 262 (55.3) 123 (33.8) 65 (41.4)** 289 (19.6) 161 (26.2)*
Diuretics 785 (83.5) 405 (85.4) 295 (81.0) 130 (82.8) 1131 (76.6) 455 (74.1)
Lipid-lowering agents 360 (38.3) 115 (24.3)* 121 (33.2) 41 (26.1)** 515 (34.9) 127 (20.7)*
Nitrates 271 (28.8) 157 (33.1)** 122 (33.5) 52 (33.1)* 322 (21.8) 131 (21.3)
Procedures, n (%)
Dialysis 21 (2.2) 25 (5.3)** 13 (3.6) 4 (2.6) 30 (2.0) 14 (2.3)
ICD 85 (9.0) 32 (6.8) 15 (4.1) 4 (2.6) 21 (1.4) 13 (2.1)
CRT 2 (0.2) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Combination medications (ACEIs/ARBs, beta blockers, aldosterone antagonists)
0 76 (8.1) 104 (21.9)* 64 (17.6) 43 (27.4)* 344 (23.3) 199 (32.4)*
Any 1 377 (40.1) 197 (41.6) 149 (40.9) 65 (41.4) 677 (45.9) 287 (46.7)
≥2 487 (51.8) 173 (36.5) 151 (41.5) 49 (31.2) 455 (30.8) 128 (20.9)
Combination medications (digoxin, diuretics, nitrates)
None or any 1 383 (40.7) 180 (38.0)** 189 (51.9) 70 (44.6) 1029 (69.7) 415 (67.6)
Any 2 410 (43.6) 200 (42.2) 135 (37.1) 70 (44.6) 384 (26.0) 164 (26.7)
All 3 147 (15.6) 94 (19.8) 40 (11.0) 17 (10.8) 63 (4.3) 35 (5.7)
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Impact of Age on Prognostic Factors That Affect
All-Cause Mortality During the First Year After
Hospital Discharge
Age is an established predictor of mortality for patients
with ADHF and other serious chronic diseases, and we
showed advanced age to be the most signiﬁcant predictor
of postdischarge mortality during the ﬁrst year after
discharge from the hospital in our regression analyses
(Table 3). In our study population, 55% of patients with rEF,
65% of patients with BpEF, and 66% of patients with pEF
were aged ≥75 years (Table 1). Consequently, we further
divided patients in the 3 EF strata into 2 age groups, <75
and ≥75 years, for purposes of examining whether there
Table 3. Multivariable Adjusted HRs for Factors Associated With Mortality at 1 Year According to Ejection Fraction Findings
Parameter
rEF (EF ≤40%) BpEF (EF 41–49%) pEF (EF ≥50%)
HR 95% CI HR 95% CI HR 95% CI
Age, y
<75 1.0 1.0 1.0
75 to 84 1.55* 1.22, 1.96* 2.02* 1.29, 3.16* 1.44* 1.14, 1.80*
≥85 2.11* 1.62, 2.76* 3.20* 1.96, 5.22* 2.12* 1.67, 2.69*
White race 1.32 0.83, 2.10 1.44 0.58, 3.61 1.36 0.86, 2.16
Length of hospital stay, days 1.02* 1.01, 1.03* 1.03* 1.00, 1.05* 1.03* 1.03, 1.04*
Comorbidities
Atrial fibrillation 0.90 0.74, 1.10 1.10 0.77, 1.58 1.37* 1.14, 1.63*
Chronic kidney disease 0.98 0.79, 1.23 1.20 0.78, 1.83 1.10 0.89, 1.36
COPD 1.28* 1.03, 1.58* 1.86* 1.29, 2.69* 1.20* 1.00, 1.44*
Coronary heart disease 1.08 0.87, 1.34 1.11 0.76, 1.62 0.97 0.81, 1.16
Heart failure 1.14 0.90, 1.45 1.31 0.88, 1.94 1.09 0.90, 1.32
Hypertension 0.88 0.71, 1.08 0.77 0.52, 1.13 0.77* 0.64, 0.93*
Peripheral vascular disease 1.31* 1.05, 1.64* 0.76 0.49, 1.19 1.04 0.84, 1.29
Stroke 1.19 0.90, 1.57 1.17 0.75, 1.82 1.01 0.78, 1.32
Laboratory and physiologic variables
BUN, mg/dL
<20 1.0 1.0 1.0
20 to 39 1.80* 1.33, 2.44* 1.34 0.86, 2.10 1.26* 1.00, 1.57*
≥40 3.96* 2.85, 5.50* 1.52 0.92, 2.52 1.94* 1.50, 2.52*
Hematocrit (%)
<30 1.0 1.0 1.0
30 to 44 0.94 0.71, 1.25 0.89 0.57, 1.39 0.73* 0.59, 0.90*
≥45 0.86 0.56, 1.33 1.35 0.63, 2.89 0.67 0.42, 1.06
Serum sodium, mEq/L
<135 1.0 1.0 1.0
≥135 0.68* 0.54, 0.84* 0.64* 0.42, 0.99* 0.77* 0.63, 0.94*
Systolic blood pressure, mm Hg
<150 1.0 1.0 1.0
150 to 159 0.66* 0.45, 0.99* 0.54* 0.31, 0.95* 0.65* 0.47, 0.89*
≥160 0.69* 0.52, 0.93* 0.74 0.47, 1.15 0.85 0.68, 1.05
Controlling variables were age, race, hospital length of stay, previously diagnosed chronic lung disease, chronic kidney disease, hypertension, peripheral vascular disease, stroke, atrial
ﬁbrillation, coronary heart disease, heart failure, blood pressure ﬁndings, serum sodium, hematocrit, and BUN values at the time of hospital admission. BpEF indicates borderline preserved
ejection fraction; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; pEF, preserved ejection fraction; rEF, reduced ejection fraction.
*Shows signiﬁcant differences.
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were differences in various prognostic factors between
younger and older patients hospitalized with ADHF
(Table 4).
The important prognostic factors that were signiﬁcantly
associated with an increased risk of dying during the ﬁrst year
after hospital discharge for ADHF for comparatively younger
patients with rEF included a history of previously diagnosed
stroke, systolic blood pressure ﬁndings <150 mm Hg on
admission, hyponatremia, and elevated BUN levels (Table 4).
Factors associated with an increased risk of dying during the
ﬁrst year after hospital discharge for those aged ≥75 years
with rEF included a history of previously diagnosed COPD or
peripheral vascular disease and those with elevated BUN
levels (Table 4).
Table 4. HRs Associated With 1-Year Death Rates After Hospital Discharge According to Age and Ejection Fraction Findings
Factor
rEF (EF ≤40%) BpEF (EF 41–49%) pEF (EF ≥50%)
<75 years ≥75 years <75 years ≥75 years <75 years ≥75 years
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI




0.68 0.46, 1.01 1.00 0.79, 1.27 2.09 0.97, 4.50 0.99 0.66, 1.50 1.86* 1.29, 2.69* 1.27* 1.04, 1.56*
Chronic kidney
disease
1.18 0.77, 1.81 0.86 0.66, 1.14 1.09 0.46, 2.59 1.33 0.80, 2.22 1.00 0.66, 1.54 1.14 0.89, 1.46
COPD 1.20 0.80, 1.80 1.37* 1.06, 1.76* 1.95 0.82, 4.65 1.63* 1.07, 2.47* 1.13 0.78, 1.62 1.14 0.93, 1.41
Coronary heart
disease
1.20 0.81, 1.78 1.01 0.78, 1.31 1.66 0.64, 4.30 0.86 0.56, 1.32 1.03 0.71, 1.49 0.93 0.76, 1.15
Heart failure 1.20 0.78, 1.85 1.15 0.86, 1.54 1.07 0.43, 2.66 1.44 0.92, 2.25 1.28 0.87, 1.90 1.07 0.86, 1.33




1.01 0.67, 1.54 1.46* 1.12, 1.92* 1.00 0.41, 2.43 0.69 0.40, 1.18 1.19 0.76, 1.84 0.98 0.77, 1.26
Stroke 1.70* 1.04, 2.79* 1.00 0.71, 1.39 0.57 0.18, 1.85 1.24 0.76, 2.03 1.20 0.72, 1.98 0.93 0.68, 1.26
Laboratory and physiologic variables
BUN levels, mg/dL
<20 1.0 1.0 1.0 1.0 1.0 1.0
20 to 39 1.81* 1.09, 3.00* 1.64* 1.11, 2.42* 1.92 0.68, 5.46 1.25 0.75, 2.08 1.18 0.77, 1.80 1.39* 1.07, 1.82*
≥40 5.02* 2.92, 8.63* 3.28* 2.16, 4.98* 2.11 0.71, 6.31 1.31 0.72, 2.38 1.23 0.75, 2.02 2.34* 1.72, 3.18*
Hematocrit (%)
<30 1.00 1.00 1.00 1.00 1.00 1.00
30 to 44 0.80 0.49, 1.32 1.03 0.72, 1.48 2.58 0.90, 7.42 0.70 0.42, 1.16 0.56* 0.37, 0.83* 0.81 0.63, 1.05
≥45 0.78 0.36, 1.69 0.98 0.57, 1.67 3.57 0.55, 23.16 1.26 0.54, 2.94 0.33* 0.14, 0.80* 0.82 0.48, 1.41
Serum sodium, mEq/L
<135 1.00 1.00 1.00 1.00 1.00 1.00
≥135 0.54* 0.37, 0.80* 0.81 0.61, 1.07 0.22* 0.10, 0.51* 1.03 0.57, 1.86 0.65* 0.43, 0.98* 0.79 0.63, 1.00
Systolic blood pressure, mm Hg
<150 1.00 1.00 1.00 1.00 1.00 1.00
150 to 159 0.68 0.35, 1.32 0.64 0.39, 1.04 0.63 0.20, 1.93 0.47* 0.24, 0.91* 0.48* 0.25, 0.96* 0.73 0.51, 1.05
≥160 0.41* 0.22, 0.77* 0.78 0.56, 1.09 0.51 0.17, 1.49 0.76 0.46, 1.26 0.84 0.52, 1.37 0.86 0.67, 1.10
Controlling variables were age, race, hospital length of stay, previously diagnosed chronic lung disease, chronic kidney disease, hypertension, peripheral vascular disease, stroke, atrial
ﬁbrillation, coronary heart disease, heart failure, estimated glomerular ﬁltration rate, blood pressure ﬁndings, serum sodium, hematocrit, and blood urea nitrogen values at the time of
hospital admission. BpEF indicates borderline preserved ejection fraction; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; pEF, preserved
ejection fraction; rEF, reduced ejection fraction.
*Shows signiﬁcant differences.
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The only statistically signiﬁcant factor that was associated
with an increased risk for dying during the ﬁrst year after
hospital discharge for younger patients with BpEF was lower
serum sodium ﬁndings at the time of hospital admission
(Table 4). For older patients with BpEF, a history of COPD was
associated with an increased risk for dying, whereas systolic
blood pressure <150 mm Hg at the time of hospital
admission was associated with an increased risk of dying.
White race, a history of atrial ﬁbrillation, systolic blood
pressure <150 mm Hg, hyponatremia, and low hematocrit
ﬁndings were signiﬁcantly associated with an increased risk of
dying for comparatively younger patients with pEF (Table 4).
Among older patients with pEF, a history of hypertension was
associated with a decreased risk of dying, whereas a history
of atrial ﬁbrillation was associated with an increased risk of
dying; elevated serum BUN ﬁndings were associated with
increased mortality during the ﬁrst year after hospital
discharge for older patients with pEF (Table 4).
Discussion
The results of this study of central Massachusetts residents
who were hospitalized among all 11 metropolitan Worcester
medical centers suggest that patients with ADHF who
survived their acute index hospitalization had high 1-year
postdischarge all-cause mortality rates. Patients with rEF
experienced the highest total death rates, whereas patients
with pEF experienced the highest postdischarge survival
rates. Advanced age, previously diagnosed COPD, systolic
blood pressure ﬁndings <150 mm Hg at the time of hospital
admission, and hyponatremia were associated with poorer
postdischarge prognosis across all EF strata. In contrast,
several prognostic factors differed between the 3 EF groups in
our univariate and multivariable adjusted analyses. When the
study population was further stratiﬁed according to age,
different prognostic factors were associated with postdis-
charge mortality in our 3 EF comparison groups.
Study Population Characteristics
Previously published observational studies and clinical trials
have primarily examined differences in the demographic and
clinical characteristics of patients with either pEF or rEF, with
few describing the characteristics of patients with BpEF.12,24–
26 These studies found that HF patients with lower EF values
had a higher burden of preexisting diseases, including
coronary heart disease and renal failure, and were primarily
male. Patients presenting with pEF ﬁndings were typically
older and mostly female. Our study agreed with the previous
literature for patients in these 2 EF strata; however, unlike
prior studies, we included patients with BpEF values. Our
ﬁndings suggest that patients with BpEF appear to represent
an intermediate group with some of the characteristics of
patients with pEF and rEF. These ﬁndings suggest that ADHF is
a heterogeneous condition with distinct group characteristics
for patients whose prognosis may differ and whose long-term
management might need to be approached differently.
Post–Hospital Discharge Mortality
There have been conﬂicting published ﬁndings as to which EF
strata have better long-term prognosis after patients develop
ADHF.11,13–17 In the present study, patients with pEF fared
better over long-term follow-up than patients with either rEF
or BpEF up to 2004. In 2006, patients with rEF fared better
than patients with BpEF, and patients with pEF ﬁndings had
the poorest survival of the 3 EF groups. This ﬁnding could be
related to more effective medications being prescribed to
patients with rEF, or it could be a chance ﬁnding resulting
from the multiplicity of comparisons carried out.
Our ﬁndings of higher survival rates in patients with pEF are
consistent with the observation that these patients typically
have more noncardiovascular comorbidities than patients with
rEF at the time of hospital admission for ADHF.27 Nevertheless,
there are no established treatments for patients with pEF,
suggesting that their lower postdischarge mortality might be
less a factor of how these patients are managed and more a
function of the underlying pathophysiology associatedwith pEF.
This is supported by the observation that ACEIs and ARBs and
speciﬁc beta blockers have been shown to be beneﬁcial in
patients with rEF but not in those with pEF.28 It is currently
unknownwhether thesemedications are as effective in patients
with BpEF as they are for patients with rEF. Regardless of the
mechanisms involved, and although all patients discharged
from the hospital after ADHF experience high long-term death
rates, more aggressive management, support, and monitoring
strategies are needed, particularly for patients with rEF.
Medication Prescribing Patterns
We observed that patients within each EF stratum were
equally likely to have been prescribed a beta blocker at the
time of hospital discharge. In addition, patients with pEF had
the highest odds of being prescribed a calcium channel
blocker; however, evidence of the effectiveness of this
medication to improve outcomes in this patient population
is lacking.29 Our ﬁndings also provide insight into differences
in the medication-prescribing practices for patients who died
over the long term compared with those who survived,
although we did not examine these associations further, given
the nonrandomized observational nature of this investigation
and the potential for confounding by treatment indication.
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Two observations stand out in our univariate analyses.
First, an analysis showed that digoxin was prescribed at the
time of hospital discharge to a greater extent for patients with
BpEF and pEF who died. Deﬁnitive evidence for digoxin
efﬁcacy in HF comes from the Digitalis Investigation Group’s
randomized clinical trial, which showed that although this
medication does not improve survival, it appears to be
associated with a reduced risk of hospitalization.30 The
second observation was that patients from all 3 EF strata who
were still alive 1 year after hospital discharge were treated
with multiple cardiac medications at the time of hospital
discharge. The prescription of multiple cardiac medications to
patients who survived the high-risk ﬁrst year after hospital
discharge suggests that future research should examine
which speciﬁc combinations of cardiac medications and
effective dosages can enhance long-term survival of patients
with ADHF, including those in differing EF strata.
Prognostic Factors Affecting Mortality During the
First Year After Hospital Discharge
Prospective studies that have classiﬁed patients with HF into
groups based on EF ﬁndings and examined predictors of
mortality have typically assessed only 2 strata, namely, those
with pEF and rEF ﬁndings.11,13–17 Consistent with the previous
literature, older age was associated with worse prognosis for
patients across EF strata. In addition, a history of COPD and
low systolic blood pressure and serum sodium ﬁndings on
admission were associated with an increased risk of dying for
patients in each EF stratum. Interestingly, we observed that a
number of factors differentiated patients with pEF and rEF that
might be important for enhanced disease management and
lifestyle practices and/or heightened surveillance.
Further stratiﬁcation of the EF groups by age had an
important impact on the factors associated with long-term
prognosis for patients in each EF stratum examined in the
present study. Atrial ﬁbrillation, peripheral vascular disease,
chronic kidney disease, and COPD, which have been reported to
be important prognostic factors in patients with ADHF,24,26,31
appeared to have a differential impact based on EF stratum and
baseline age. Future clinical trials should include older patients
with different comorbidities to better understand the effects of
age and selected comorbidities on the long-term prognosis of
patients with ADHF, its various EF strata, and the enhanced
management of this clinical syndrome and its various subtypes.
Discrepancies between the current ﬁndings and the
previous literature with regard to variables affecting the
long-term prognosis of patients with ADHF could be related to
a number of factors including comparatively small numbers of
women studied, use of clinical trial data, different HF
diagnostic criteria, exclusion of patients with BpEF,11 duration
of follow-up, and speciﬁc EF strata used. Future studies
should use the same EF strata as those proposed in the 2013
AHA/ACC guidelines2 to ensure that studies can be ade-
quately compared. Further work is needed to understand the
impact of various chronic conditions and sociodemographic,
psychosocial, and clinical factors on the overall mortality of
patients with ADHF by currently recommended EF strata.
Study Strengths and Limitations
Our study has several strengths including its population-based
design and inclusion of only validated cases of ADHF that
occurred among adult patients of all ages from a well-deﬁned
and characterized large metropolitan area. In contrast,
because this New England community is predominantly white,
the generalizability of our ﬁndings to other races and
ethnicities may be limited. In addition, more contemporary
data are needed to extend the present ﬁndings. We did not
collect information on patients’ socioeconomic, psychosocial,
or cognitive status or other factors that have been shown to
affect long-term prognosis after ADHF; we also did not assess
changes in various physiological factors or laboratory ﬁndings
during each patient’s index admission that may have been
associated with reduced or increased risk of dying or the role
of novel serum biomarkers. Only those patients who had
echocardiograms done for clinical indications were included in
the analysis, and a large percentage of patients in our
surveillance study did not have an echocardiogram performed
during the index hospitalization and were excluded from the
present investigation. Finally, we had only a single EF
measurement available from the index hospitalization for
each patient. Because EF ﬁndings may change over time,32 we
cannot account for the impact of potentially changing EF
values over time and how those changes may have affected
the mortality proﬁles of at-risk patients.
Conclusions
Patients with ADHF experience high death rates after
discharge from the hospital, regardless of EF ﬁndings. The
highest postdischarge mortality rates were observed for
patients with rEF. Prognostic factors associated with mortality
during the ﬁrst year after hospital discharge for ADHF differed
among patients in the various EF strata, with advanced age
having a large impact on which prognostic factors were
important determinants of mortality. This study highlights the
need for further research into the effectiveness of presently
available treatments for patients with varying EF ﬁndings and
reinforces ongoing discussions about different treatment
guidelines that may be needed for patients with pEF, rEF,
and BpEF to design more personalized treatment plans.
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